4
Changes in Ownership
UroGen Pharma Ltd. Filed Acc 0001209191-22-006385
Chief Financial Officer sold 331 shares at $7.58 ($2,509)
- Chief Financial Officer acquired 666 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Henderson Molly · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-01-31 | Exercise or conversion : show line 1 in the form | +666 | 5,579 | D | ||
| 2022-01-31 | Sale : show line 2 in the form | −331 | $7.58 | $2,509 | 5,248 | D |
| Open-market sales · 331 sh · avg $7.58 · $2,509 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2022-01-31 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −666 | 1,334 | 1,334 | D | ||
| 2022-01-31 | Grant or award : show line 4 in the form Restricted Stock Units | +7,500 | 7,500 | 7,500 | D | ||
| 2022-01-31 | Grant or award : show line 5 in the form Stock Option (right to buy) | +30,000 | $7.72 | 2032-01-31 | 30,000 | 30,000 | D |
Loading xslF345X03/doc4.xml…